Tweet
Share
Myworld |
Sign Up
|
Login
Home
Browse
Featured
Latest
Popular
Templates
Patients
Blog
ACLS updated
Send This
Download
Comment
Favourite
more
Add to your Conference/Group
Please Select--
Add your comments:
Insert YouTube Videos inside your Slideworld presentation Copy and paste the video URL from YouTube, choose where to insert the video, and press “Submit”. The video will play in your slideshow after sometime.
Enter YouTube video URL
Enter Slide No where you want to insert youtube videos
Rating :
Rate It:
Embed :
Post a comment
Post Comment on Twitter
Post Comment on SlideWorld
Comments:
Subscribe to follow-up comments
SlideWorld will not store your password. SlideWorld will maintain your privacy.
Twitter Username:
Twitter Password:
Comments:
Email:
Subscribe to follow-up comments
1 Favorites
anasbilal
, favourited this 3 Years ago.
First
Prev
[1]
Next
Last
Notes
Show Notes
Hide Notes
Slide 1 :
ACLS updated Management of Symptomatic Bradycardia and Tachycardia 2006.02.23 R ? ? ?
Slide 2 :
For patients with acute coronary ischemia, the greatest risk for serious arrhythmias occurs during the first 4 hours after the onset of symptoms. ECG monitoring should be established as soon as possible.
Slide 3 :
Principles of Arrhythmia Recognition and Management
Slide 4 :
Total patient assessment. Ventilation, oxygenation, heart rate, blood pressure, and level of consciousness. Signs of inadequate organ perfusion.
Slide 5 :
If bradycardia produces signs and symptoms that persist despite adequate airway and breathing, prepare to provide pacing. For symptomatic high-degree AV block, provide transcutaneous pacing without delay. If the tachycardic patient is unstable with severe signs and symptoms related to tachycardia, prepare for immediate cardioversion.
Slide 6 :
If the patient with tachycardia is stable, determine if the patient has a narrow-complex or wide-complex tachycardia and then tailor therapy accordingly. Call for expert consultation regarding complicated rhythm interpretation, drugs, or management decisions.
Slide 7 :
Bradycardia
Slide 8 :
6H + 5T Hypovolemia Toxins Hypoxia Tamponade, cardiac Hydrogen Tension pneumothorax Hyper/HypoK Thrombosis (cardiac/ pul) Hypoglycemia Trauma (IICP) Hypothermia
Slide 9 :
Therapy Pacing (class I): transcutaneous/transvenous Atropine (class IIa) 0.5 mg IV every 3 ~ 5 minutes to a maximum total dose of 3 mg. Second line (class IIb) epinephrine, dopamine, glucagon
Slide 10 :
Tachycardia
Slide 11 :
Classification of Tachyarrhythmias Narrow–QRS-complex — Sinus tachycardia — Atrial fibrillation — Atrial flutter — AV nodal reentry — Accessory pathway–mediated tachycardia — Atrial tachycardia (ectopic and reentrant) — Multifocal atrial tachycardia (MAT) — Junctional tachycardia
Slide 12 :
Wide–QRS-complex — Ventricular tachycardia (VT) — SVT with aberrancy — Pre-excited tachycardias (advanced recognition rhythms using an accessory pathway)
Slide 13 :
Slide 14 :
Slide 15 :
Slide 16 :
Supraventricular Tachycardia
Slide 17 :
Therapy Preferred initial therapeutic choices --Vagal Maneuvers: terminate 20~25% reentry SVT. --Adenosine--6 mg (class I), then 12 mg, 12 mg. --safe and effective in pregnancy. --3 mg if given by central venous access. Second-line --Calcium Channel Blockers --Beta-blockers
Slide 18 :
Irregular Tachycardias Atrial Fibrillation and Flutter
Slide 19 :
Therapy Rate control versus Rhythm control AF > 48hrs, anticoagulation first (keep INR 2~3); Electric or pharmacologic cardioversion should not be attempted in these patients unless the patient is unstable or the absence of a LA thrombus is documented by TEE. Magnesium (LOE 3), diltiazem (LOE 2), and beta-blockers (LOE 2) for rate control. Amiodarone, ibutilide, propafenone, flecainide, digoxin, clonidine, or magnesium can be considered for rhythm control.
Slide 20 :
Wide-Complex Tachycardia
Slide 21 :
Evaluation First: stable or unstable Second: 12-lead ECG Third: rhythm --- regular: VT or SVT with aberrancy --- irregular: AF with aberrancy pre-excited AF (AF with WPW) polymorphic VT
Slide 22 :
Therapy Regular Wide-Complex Tachycardias ---SVT: adenosine ---monomorphic VT ---symptomatic: synchronized cardioversion. ---stable: amiodarone (IIa), 150 mg, 10min (2.2 g, 24 hr)
Slide 23 :
Polymorphic (Irregular) VT
Slide 24 :
Therapy Unstable: unsynchronized shocks. Polymorphic VT with long QT (torsades de pointes VT): magnesium. Polymorphic VT (normal QT interval): amiodarone Torsades de pointes associated with bradycardia and drug-induced QT prolongation: isoproterenol or ventricular pacing.
Carotid Stenting - U...
Evidence Update in IBS
update on atrial flutter
Lung Cancer Update ...
Treatment of Bipolar...
ENDEAVOR Clinical Pr...
Free Powerpoint Templates
SlidesOnline
4 Years ago.
7093 Views, 2 favourite
Atrial fibrillation — Atrial flutter — AV nodal reentry — Accessory pathway–mediatedVentricular tac
more
Atrial fibrillation — Atrial flutter — AV nodal reentry — Accessory pathway–mediatedVentricular tachycardia (VT) — SVT with aberrancy — Pre-excited
less
More By User
Flag as inappropriate
Select your reason for flagging this presentation as inappropriate. If needed, use the
feedback
form to let us know more details.
None
Pornographic
Defamatory
Illegal/Unlawful
Other Terms Of Service Violation
Copy Right
Cancel
Browse
|
Powerpoint Templates
|
Tags
|
Contact
|
About Us
|
Privacy
|
FAQ
|
Blog
© Slideworld